[
  {
    "ts": null,
    "headline": "Regeneron Culls Losses After High-Dose Eylea Sales Disappoint",
    "summary": "Regeneron stock recovered Monday after the drugmaker preannounced light sales of a high-dose version of eye drug Eylea.",
    "url": "https://finnhub.io/api/news?id=48bb6725b5a9af0e3dfac0f9026957a019d313e6d7cdf284796cf00bbcb283df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736803020,
      "headline": "Regeneron Culls Losses After High-Dose Eylea Sales Disappoint",
      "id": 132439114,
      "image": "https://media.zenfs.com/en/ibd.com/4795b98ccb889179b7e4c69d8fd230c8",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron stock recovered Monday after the drugmaker preannounced light sales of a high-dose version of eye drug Eylea.",
      "url": "https://finnhub.io/api/news?id=48bb6725b5a9af0e3dfac0f9026957a019d313e6d7cdf284796cf00bbcb283df"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 43rd Annual J.P.",
    "url": "https://finnhub.io/api/news?id=6f8da781dd6c34f501446a109b62b9f68ae31eb4c8ad15869d68fce533f7df72",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736795292,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)",
      "id": 132390220,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 43rd Annual J.P.",
      "url": "https://finnhub.io/api/news?id=6f8da781dd6c34f501446a109b62b9f68ae31eb4c8ad15869d68fce533f7df72"
    }
  },
  {
    "ts": null,
    "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
    "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
    "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736791802,
      "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
      "id": 132390023,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1886168184/image_1886168184.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
      "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835"
    }
  },
  {
    "ts": null,
    "headline": "Illumina and Regeneron invest $139.5m in Truveta to build largest genetic database",
    "summary": "The Truveta Genome Project aims to establish the world’s largest and most diverse database of genetic information.",
    "url": "https://finnhub.io/api/news?id=24b9de85f4cfad9843711bc3f4c03d2246c9c949404ffd47f294846feac79af9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736789108,
      "headline": "Illumina and Regeneron invest $139.5m in Truveta to build largest genetic database",
      "id": 132439116,
      "image": "https://www.medicaldevice-network.com/wp-content/uploads/sites/23/2025/01/shutterstock_2534299873.jpg",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The Truveta Genome Project aims to establish the world’s largest and most diverse database of genetic information.",
      "url": "https://finnhub.io/api/news?id=24b9de85f4cfad9843711bc3f4c03d2246c9c949404ffd47f294846feac79af9"
    }
  },
  {
    "ts": null,
    "headline": "43rd Annual J.P. Morgan Healthcare Conference 2025",
    "summary": "The following slide deck was published by Regeneron Pharmaceuticals, Inc.",
    "url": "https://finnhub.io/api/news?id=5b0eb962b04c5075a9317bd1b120db56f492b8dc66c7c64a3910ffe19034b3b9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736788482,
      "headline": "43rd Annual J.P. Morgan Healthcare Conference 2025",
      "id": 132389827,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "The following slide deck was published by Regeneron Pharmaceuticals, Inc.",
      "url": "https://finnhub.io/api/news?id=5b0eb962b04c5075a9317bd1b120db56f492b8dc66c7c64a3910ffe19034b3b9"
    }
  },
  {
    "ts": null,
    "headline": "REGN Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit",
    "summary": "Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. and certain of its...",
    "url": "https://finnhub.io/api/news?id=a88a02810deeb444c8c22242e35f6677b999033faa8859a2833c3bc98ada6b53",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736784064,
      "headline": "REGN Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit",
      "id": 132389441,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. and certain of its...",
      "url": "https://finnhub.io/api/news?id=a88a02810deeb444c8c22242e35f6677b999033faa8859a2833c3bc98ada6b53"
    }
  },
  {
    "ts": null,
    "headline": "ATTENTION NASDAQ: REGN INVESTORS",
    "summary": "PHILADELPHIA, Jan. 13, 2025 /PRNewswire/ -- A securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. . The lawsuit has been filed on behalf of purchasers of...",
    "url": "https://finnhub.io/api/news?id=78569b3bb86b6853a6ff6d5c2f1d71ea24c96fcc2c97e49731bb876a437fa020",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736783105,
      "headline": "ATTENTION NASDAQ: REGN INVESTORS",
      "id": 132389379,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "PHILADELPHIA, Jan. 13, 2025 /PRNewswire/ -- A securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. . The lawsuit has been filed on behalf of purchasers of...",
      "url": "https://finnhub.io/api/news?id=78569b3bb86b6853a6ff6d5c2f1d71ea24c96fcc2c97e49731bb876a437fa020"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?",
    "summary": "REGN's Eylea faces a rapid decline in sales, impacting overall performance even though Dupixent maintains momentum. We advise investors to stay on the sidelines for now.",
    "url": "https://finnhub.io/api/news?id=06e3000d81d69d3e9d2f030331822058a39c3c2479650d8c33f27f0ed86cf8f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736774520,
      "headline": "Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?",
      "id": 132439117,
      "image": "https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN's Eylea faces a rapid decline in sales, impacting overall performance even though Dupixent maintains momentum. We advise investors to stay on the sidelines for now.",
      "url": "https://finnhub.io/api/news?id=06e3000d81d69d3e9d2f030331822058a39c3c2479650d8c33f27f0ed86cf8f1"
    }
  },
  {
    "ts": null,
    "headline": "Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit",
    "summary": "Glancy Prongay & Murray LLP reminds investors of the upcoming March 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise...",
    "url": "https://finnhub.io/api/news?id=a4f3d66c52558a80f46f1d60ebdfc0b862121f21b9da460216171d61ce4bd743",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736769663,
      "headline": "Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit",
      "id": 132388512,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Glancy Prongay & Murray LLP reminds investors of the upcoming March 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise...",
      "url": "https://finnhub.io/api/news?id=a4f3d66c52558a80f46f1d60ebdfc0b862121f21b9da460216171d61ce4bd743"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference",
    "summary": "Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD pre-filled syringe (PFS) submission completed; launch expected by mid-2025 Libtayo® exceeded $1 billion in 2024 annual ne",
    "url": "https://finnhub.io/api/news?id=97e765c6e46a31ab8be869cef5f77946c86e6832826fbdb6cbc1d066588c4e58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736767800,
      "headline": "Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference",
      "id": 132439119,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD pre-filled syringe (PFS) submission completed; launch expected by mid-2025 Libtayo® exceeded $1 billion in 2024 annual ne",
      "url": "https://finnhub.io/api/news?id=97e765c6e46a31ab8be869cef5f77946c86e6832826fbdb6cbc1d066588c4e58"
    }
  },
  {
    "ts": null,
    "headline": "Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial",
    "summary": "Primary endpoint of DFS met at first prespecified interim analysis, showing a 68% reduction in the risk of disease recurrence or death in patients with high-risk CSCC after surgery compared to placebo Libtayo is the first and only immunotherapy to show a statistically significant and clinically meaningful benefit in high-risk CSCC in the adjuvant setting; a recent Phase 3 trial with Keytruda® failed in the same setting1 Libtayo is standard of care for certain patients with advanced CSCC TARRYTOW",
    "url": "https://finnhub.io/api/news?id=e8f2eeaaf2cbdf79172e0e301e46cb128824214196697faebc672796e30e4a7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736766900,
      "headline": "Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial",
      "id": 132439120,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Primary endpoint of DFS met at first prespecified interim analysis, showing a 68% reduction in the risk of disease recurrence or death in patients with high-risk CSCC after surgery compared to placebo Libtayo is the first and only immunotherapy to show a statistically significant and clinically meaningful benefit in high-risk CSCC in the adjuvant setting; a recent Phase 3 trial with Keytruda® failed in the same setting1 Libtayo is standard of care for certain patients with advanced CSCC TARRYTOW",
      "url": "https://finnhub.io/api/news?id=e8f2eeaaf2cbdf79172e0e301e46cb128824214196697faebc672796e30e4a7f"
    }
  },
  {
    "ts": null,
    "headline": "Truveta sells stakes to Regeneron, Illumina in deal to build genetic database",
    "summary": "Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals, Illumina and 17 U.S. health systems will take a $320 million stake in the company as part of a deal to build the world's largest genetic database.  Biotechnology company Regeneron pledged to put in $120 million and genetic sequencing company Illumina is investing $20 million.  The rest will come from U.S. health systems including New York-based Northwell Health, multi-state non-profit Trinity Health and Advocate Health, based in Chicago.",
    "url": "https://finnhub.io/api/news?id=1e7be8b436b24dedad14257ea41a679a66bff4aced1bf6d470ff6d5d59f62605",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736766459,
      "headline": "Truveta sells stakes to Regeneron, Illumina in deal to build genetic database",
      "id": 132439122,
      "image": "https://media.zenfs.com/en/reuters-finance.com/1c23622222d948915177f1db2ac361a0",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals, Illumina and 17 U.S. health systems will take a $320 million stake in the company as part of a deal to build the world's largest genetic database.  Biotechnology company Regeneron pledged to put in $120 million and genetic sequencing company Illumina is investing $20 million.  The rest will come from U.S. health systems including New York-based Northwell Health, multi-state non-profit Trinity Health and Advocate Health, based in Chicago.",
      "url": "https://finnhub.io/api/news?id=1e7be8b436b24dedad14257ea41a679a66bff4aced1bf6d470ff6d5d59f62605"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery",
    "summary": "The Truveta collaboration will extend Regeneron Genetics Center’s® (RGCTM) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers) through genetic sequencing of up to ten million additional patient volunteers, all with linked electronic health records, creating the Truveta Genome Project Extensively expanded database effort is designed to dramatically accelerate discovery of new genetics-based drug targets and therapies, while a",
    "url": "https://finnhub.io/api/news?id=8a7c58cde9695819ebab193323e11902da2e0bb81676116713ca531dd8bc8240",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736766300,
      "headline": "Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery",
      "id": 132439123,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The Truveta collaboration will extend Regeneron Genetics Center’s® (RGCTM) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers) through genetic sequencing of up to ten million additional patient volunteers, all with linked electronic health records, creating the Truveta Genome Project Extensively expanded database effort is designed to dramatically accelerate discovery of new genetics-based drug targets and therapies, while a",
      "url": "https://finnhub.io/api/news?id=8a7c58cde9695819ebab193323e11902da2e0bb81676116713ca531dd8bc8240"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Working with Truveta's Network to Extend Database",
    "summary": "By Dean Seal Regeneron Pharmaceuticals said it is collaborating with Truveta and its network of U.S. health systems to extend its DNA sequence-linked healthcare database. The company said...",
    "url": "https://finnhub.io/api/news?id=cf3124dbd7f25a2debd2614cd573324ad874d7d9e38e68b4333af3bc7ad90c2c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736754609,
      "headline": "Regeneron Working with Truveta's Network to Extend Database",
      "id": 132386994,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "By Dean Seal Regeneron Pharmaceuticals said it is collaborating with Truveta and its network of U.S. health systems to extend its DNA sequence-linked healthcare database. The company said...",
      "url": "https://finnhub.io/api/news?id=cf3124dbd7f25a2debd2614cd573324ad874d7d9e38e68b4333af3bc7ad90c2c"
    }
  },
  {
    "ts": null,
    "headline": "REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit",
    "summary": "Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. securities between November 2, 2023 and October 30, 2024, both dates inclusive , have until...",
    "url": "https://finnhub.io/api/news?id=720e4d744352ffc81ffb05cda36bc61f32255190ef9d0464e2245067e3bfa807",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736747343,
      "headline": "REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit",
      "id": 132386313,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. securities between November 2, 2023 and October 30, 2024, both dates inclusive , have until...",
      "url": "https://finnhub.io/api/news?id=720e4d744352ffc81ffb05cda36bc61f32255190ef9d0464e2245067e3bfa807"
    }
  },
  {
    "ts": null,
    "headline": "The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN",
    "summary": "NEW YORK, Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . ...",
    "url": "https://finnhub.io/api/news?id=a2bb566652976d01e958f0fb7ba2756c046b8fd828c8100577707244d304c4dc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736747188,
      "headline": "The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN",
      "id": 132386259,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "NEW YORK, Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . ...",
      "url": "https://finnhub.io/api/news?id=a2bb566652976d01e958f0fb7ba2756c046b8fd828c8100577707244d304c4dc"
    }
  }
]